Project Grant R03CA303913
Award Date 9/5/25
Completion Date 8/31/27
Dollars Obligated $149K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Indiana, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $305,031 Project Grant to Round Table Research, Inc. under the Cancer Treatment Research program (CFDA 93.395) to advance extracellular vesicle (EV) therapy for the treatment of glioblastoma (GBM), an aggressive form of brain cancer. The funded project, conducted in collaboration with researchers at the University of North Carolina-Chapel Hill, seeks to develop engineered tumoricidal EVs derived from induced neural stem cells (iNSCs) as a promising...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $192,240 to The University of Texas MD Anderson Cancer Center to conduct research on the functional contribution of extracellular vesicles in pancreatic cancer. The research aims to investigate how cancer cell-derived extracellular vesicles modulate the tumor microenvironment to facilitate pancreatic cancer initiation, progression, and metastasis. The goal is to identify novel...
- This $429,399 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research by Cedars-Sinai Medical Center in California. The research aims to elucidate the role of extracellular vesicle-enclosed circular RNAs in modulating the immune response to prostate cancer. Specifically, the study will investigate the transfer of extracellular vesicles from prostate cancer cells to macrophages and how the enclosed circular RNAs can trigger...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) is supporting a research effort led by The Trustees of Columbia University in the City of New York to develop novel inhalable extracellular vesicles (exosomes) for enhanced delivery of interleukin-12 (IL12) to treat lung cancer. The $128,228 award, spanning July 1, 2025 to June 30, 2027, aims to engineer exosome-based RNA delivery platforms that can achieve high mRNA encapsulation, scalability,...
- This Project Grant award, in the amount of $1,221,128.00, was provided by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the University of Massachusetts Boston. The funding will support a 3-year research project to investigate the biomechanical and biomolecular properties of large extracellular vesicles (L-EVs), which play important roles in cell-to-cell communication and have potential as disease biomarkers and therapeutic carriers. The research team, with...
- The National Cancer Institute (NCI) awarded a $2,855,619 Project Grant titled "Empowering Cancer Detection and Monitoring with CAMPEX - CRISPR-Accelerated Molecular Profiling of Extracellular Vesicles" to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant, under the Cancer Detection and Diagnosis Research Federal Grant Program (CFDA 93.394), aims to advance CAMPEX, an integrated platform for highly sensitive and precise analysis of...
- The National Cancer Institute (NCI) awarded a $226,504 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Rector & Visitors of the University of Virginia (UVA) to elucidate the role of B/T cell-enriched immune aggregates in immune surveillance against triple-negative breast cancer (TNBC). The project aims to study how these novel immune aggregates form and function to control pre-malignant progression of TNBC, which could inform future strategies to enhance immune surveillance...
- This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) is funding research at Yale University to investigate the role of the enzyme TENT2 in regulating microRNA-1 (miR-1) degradation in tumor endothelial cells (TECs) and its impact on tumor angiogenesis and progression in non-small cell lung cancer (NSCLC). The $430,684 award, which runs from July 2024 to June 2026, will support two specific aims: 1) determining the role of TENT2 in...
- This $421,685 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by the University of California, San Francisco (UCSF) to investigate the "reactive" immune system in tumors and the tumor microenvironment. The study aims to discover discrete immune cell niches within the tumor that can enhance the effectiveness of cancer immunotherapies. Using innovative spatial transcriptomics, genetic tools, and cellular...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine provides $696,569.00 in funding to advance research on a novel therapy for lung cancer. The research aims to characterize the role of the protein lipocalin 2 (LCN2) in the tumor microenvironment and develop antibody-based therapeutics that interfere with LCN2 function, both as monotherapy and in combination with immune checkpoint blockade. This 5-year...